If You Are Living With HIV
If you are living with HIV, you may be eligible to participate in one of our clinical trials. Please click the links below if you would like more information about our open trials. If you are interested in participating, please contact Melissa La Mar at 212-327-7280 or e-mail her at mlamar@adarc.org.Clinical Trials for Patients Living with HIV
(MMA-0754)
Viral and Host factors in the transmission and pathogenesis of HIV
Viral and Host factors in the transmission and pathogenesis of HIV
A Phase 2b Randomized, Double-Blind, Double-Dummy Trial of Once-Daily Doses of Cenicriviroc or Once-Daily EFV, Each With Open-Label FTC/TDF, in HIV-1-Infected, Antiretroviral Treatment-Naïve, Adult Patients
(MMA-0591)
HIV Elite Controller Study
HIV Elite Controller Study
The focus of the studies to be conducted under this protocol and consent form is on the detailed analysis of host cellular and humoral immune responses, comprehensive human genome analysis and genomic analysis of the infecting viruses isolated from persons that control HIV Infection.
(MMA 0606) An Inter-disciplinary Approach to HIV and Other Infectious Diseases of Drug Users
The reason for doing this research is to determine whether injecting drugs can make HIV infection worse - that is cause activation of the immune system which increases the destruction of the immune system.
One way to measure HIV disease is by looking at the gut, or gastrointestinal tract. The body produces many types of immune cells in the gut, including T-cells that are the primary target of HIV. It is thought that injecting drugs may activate the immune system which in turn may increase destruction of immune cells in the gut. To test this theory, we are obtaining biopsies from the lower intestines of HIV + injection drug users, HIV+ people who do not inject drugs and people who do not use drugs and are HIV-.
One way to measure HIV disease is by looking at the gut, or gastrointestinal tract. The body produces many types of immune cells in the gut, including T-cells that are the primary target of HIV. It is thought that injecting drugs may activate the immune system which in turn may increase destruction of immune cells in the gut. To test this theory, we are obtaining biopsies from the lower intestines of HIV + injection drug users, HIV+ people who do not inject drugs and people who do not use drugs and are HIV-.
(MMA 0639) Acute HIV-1 Infection Prospective Cohort Study
The purpose of this research study is to understand how people’s infection fighting (immune) system reacts to HIV. We want to know how the body, including blood and other fluids from the body, works if someone has or comes into contact with HIV. We also want to examine the genes in your body, called DNA, since they might affect how your body responds to HIV. Eligible participants will be placed into one of the following four study groups:
Group 1: Proven acute (recent) HIV-1 infection: approximately 500 total
Group 1A: Sexual partners of members of Group 1: approximately 400 total
Group 2: Established HIV-1 infection: approximately 350 total
Group 3: HIV-1 negative: approximately 50 total
We will only enroll volunteers for Group 1 at The Rockefeller University Hospital.
Group 1: Proven acute (recent) HIV-1 infection: approximately 500 total
Group 1A: Sexual partners of members of Group 1: approximately 400 total
Group 2: Established HIV-1 infection: approximately 350 total
Group 3: HIV-1 negative: approximately 50 total
We will only enroll volunteers for Group 1 at The Rockefeller University Hospital.
(MMA 0728) A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy
A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV-1 infected antiretroviral therapy naive adult subjects (GSK ING114467)